Table 3

Disease activity parameters at weeks 0, 12 and 24 by treatment group

Placebo week 0–12
Adalimumab week 0–24Adalimumab week 12–24
Week 0Week 12Week 24Week 0Week 12Week 24
(n=20)(n=19)(n=19)(n=20)(n=19)(n=17)
Patient's global assessment, 0–100 mm VAS65.8 (18.1)33.3 (26.6)*22.5 (20.2)*68.4 (17.4)62.2 (21.5)34.9 (25.7)*,**
Physician's global assessment, 0–100 mm VAS47.8 (11.8)28.4 (20.9)*18.4 (14.8)*,**57.0 (12.6)52.1 (18.9)33.8 (21.0)*,**
Swollen joint count, 0–66 joints4.3 (4.2)1.9 (2.2)*0.6 (1.0)*,**2.5 (1.9)2.2 (1.1)1.3 (0.8)*,**
Tender joint count, 0–68 joints9.4 (8.2)7.9 (14.0)4.6 (6.9)*10.6 (5.9)12.6 (8.8)7.8 (7.0)**
BASDAI5.5 (2.3)3.8 (3.2)*2.5 (2.1)*,**6.0 (1.4)5.7 (1.7)3.6 (2.4)*,**
ASDAS2.9 (1.0)1.8 (1.2)*1.4 (0.8)*3.2 (0.9)3.1 (0.9)1.9 (0.9)*,**
CRP, mg/l7.8 (13.3)2.5 (2.2)2.1 (2.8)13.5 (26.4)12.8 (24.7)7.9 (24.0)
ESR, mm/h11.6 (13.5)6.1 (7.2)4.9 (2.7)*15.7 (23.1)13.1 (13.7)4.1 (2.6)*
HAQ-DI0.8 (0.6)0.6 (0.7)*0.4 (0.6)*1.1 (0.5)1.0 (0.4)0.6 (0.4)*,**
HUI-30.48 (0.35)0.60 (0.40)0.67 (0.36)*0.38 (0.28)0.46 (0.34)0.59 (0.31)*
  • *p Value <0.05 compared with week 0 (by treatment group).

  • **p Value <0.05 week 24 compared with week 12 (by treatment group).

  • Values are the mean (SD). Significance of the comparisons is determined by a paired t test.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; HUI-3, Health Utility Index Mark 3; VAS, visual analogue scale.